Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus

• Main Authors: Josidel Conceição Oliver (Author), Evandro Neves Silva (Author), Letícia Martins Soares (Author), Gislaine Cristina Scodeler (Author), Ana de Souza Santos (Author), Patrícia Paiva Corsetti (Author), Carlos Roberto Prudêncio (Author), Leonardo Augusto de Almeida (Author)
• Format: Book
• Published: SAGE Publishing, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2515-1363; 10.1177/25151355221144845
• Keywords: Therapeutics. Pharmacology; RM1-950; Immunologic diseases. Allergy; RC581-607
• Source: Therapeutic Advances in Vaccines and Immunotherapy, Vol 10 (2022)

According to the World Health Organization (WHO), in the second half of 2022, there are about 606 million confirmed cases of COVID-19 and almost 6,500,000 deaths around the world. A pandemic was declared by the WHO in March 2020 when the new coronavirus spread around the world. The short time between the first cases in Wuhan and the declaration of a pandemic initiated the search for ways to stop the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or to attempt to cure the disease COVID-19. More than ever, research groups are developing vaccines, drugs, and immunobiological compounds, and they are even trying to repurpose drugs in an increasing number of clinical trials. There are great expectations regarding the vaccine's effectiveness for the prevention of COVID-19. However, producing sufficient doses of vaccines for the entire population and SARS-CoV-2 variants are challenges for pharmaceutical industries. On the contrary, efforts have been made to create different vaccines with different approaches so that they can be used by the entire population. Here, we summarize about 8162 clinical trials, showing a greater number of drug clinical trials in Europe and the United States and less clinical trials in low-income countries. Promising results about the use of new drugs and drug repositioning, monoclonal antibodies, convalescent plasma, and mesenchymal stem cells to control viral infection/replication or the hyper-inflammatory response to the new coronavirus bring hope to treat the disease.